Melanotan I
Also known as: Melanotan 1, Afamelanotide, Scenesse, MT-1
An FDA-approved melanocortin agonist for skin pigmentation and photoprotection.
Overview
Melanotan I (Afamelanotide) is a synthetic analog of alpha-melanocyte stimulating hormone (α-MSH) that stimulates melanin production. Unlike Melanotan II, it is more selective for pigmentation without significant sexual side effects. It is FDA-approved for erythropoietic protoporphyria (EPP).
Mechanism of Action
Agonist at melanocortin 1 receptor (MC1R) on melanocytes. Stimulates melanogenesis and eumelanin production. Provides photoprotection by increasing skin pigmentation. More selective than MT-II.
Pharmacokinetics
Half-life ~30 minutes. Administered as subcutaneous implant (Scenesse) for slow release over ~60 days.
Dosing Protocols
Note: These are research protocols from literature. This is not medical advice.
EPP (Scenesse)
16 mg implant
Every 60 days
Before/during sunny seasons
FDA-approved protocol
Research (injection)
0.5-1 mg
Daily for loading, then maintenance
Variable
Off-label use
Research Areas
Key Research Findings
- 1FDA-approved for EPP (Scenesse)
- 2Increases skin melanin density
- 3Provides photoprotection in light-sensitive patients
- 4More selective than Melanotan II
Side Effects & Contraindications
Reported Side Effects
- Nausea
- Flushing
- Fatigue
- Headache
- Skin darkening
- Mole darkening
Contraindications
- Melanoma or history of melanoma
- Severe hepatic impairment
- Severe renal impairment
Safety Considerations
FDA approved for EPP. Monitor for mole changes. Theoretical melanoma concern (not proven). Does not significantly affect libido unlike MT-II.
Storage Requirements
Refrigerate 2-8°C
Scientific References
- 1